Last reviewed · How we verify

Intranasal Ketorolac Tromethamine

Tehran University of Medical Sciences · Phase 3 active Small molecule

Ketorolac tromethamine is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis and provide rapid pain relief and anti-inflammatory effects.

Ketorolac tromethamine is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis and provide rapid pain relief and anti-inflammatory effects. Used for Acute moderate to severe pain, Postoperative pain, Migraine headache.

At a glance

Generic nameIntranasal Ketorolac Tromethamine
Also known asAtomized Intranasal Ketorolac
SponsorTehran University of Medical Sciences
Drug classNonsteroidal anti-inflammatory drug (NSAID)
TargetCyclooxygenase (COX-1 and COX-2)
ModalitySmall molecule
Therapeutic areaPain Management
PhasePhase 3

Mechanism of action

Ketorolac works by blocking COX-1 and COX-2 enzymes, which are responsible for producing prostaglandins that mediate inflammation, pain, and fever. The intranasal formulation allows for rapid systemic absorption and faster onset of action compared to oral routes, making it suitable for acute pain management. This route of administration bypasses first-pass hepatic metabolism and provides analgesic effects within minutes.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: